NOVARTIS OCTREOTIDE LAR octreotide (as acetate) 30 mg modified release injection vial plus diluent prefilled syringe composite p Australia - English - Department of Health (Therapeutic Goods Administration)

novartis octreotide lar octreotide (as acetate) 30 mg modified release injection vial plus diluent prefilled syringe composite p

novartis pharmaceuticals australia pty ltd - octreotide -

NOVARTIS OCTREOTIDE LAR octreotide (as acetate) 20 mg modified release injection vial plus diluent prefilled syringe composite p Australia - English - Department of Health (Therapeutic Goods Administration)

novartis octreotide lar octreotide (as acetate) 20 mg modified release injection vial plus diluent prefilled syringe composite p

novartis pharmaceuticals australia pty ltd - octreotide -

NOVARTIS OCTREOTIDE LAR octreotide (as acetate) 10 mg modified release injection vial plus diluent prefilled syringe composite p Australia - English - Department of Health (Therapeutic Goods Administration)

novartis octreotide lar octreotide (as acetate) 10 mg modified release injection vial plus diluent prefilled syringe composite p

novartis pharmaceuticals australia pty ltd - octreotide -

Imprida HCT European Union - English - EMA (European Medicines Agency)

imprida hct

novartis europharm ltd. - amlodipine, valsartan, hydrochlorothiazide - hypertension - angiotensin ii antagonists, plain, angiotensin ii antagonists, combinations - treatment of essential hypertension as substitution therapy in adult patients whose blood pressure is adequately controlled on the combination of amlodipine, valsartan and hydrochlorothiazide (hct), taken either as three single-component formulations or as a dual-component and a single-component formulation.

Enviage European Union - English - EMA (European Medicines Agency)

enviage

novartis europharm ltd. - aliskiren - hypertension - agents acting on the renin-angiotensin system - treatment of essential hypertension

Trazec European Union - English - EMA (European Medicines Agency)

trazec

novartis europharm ltd. - nateglinide - diabetes mellitus, type 2 - drugs used in diabetes - nateglinide is indicated for combination therapy with metformin in type 2 diabetic patients inadequately controlled despite a maximally tolerated dose of metformin alone.

Fluorescein Novartis Australia - English - Department of Health (Therapeutic Goods Administration)

fluorescein novartis

novartis pharmaceuticals australia pty ltd - fluorescein sodium -

CO-DIOVAN 8012.5 MG FILM COATED TABLETS Israel - English - Ministry of Health

co-diovan 8012.5 mg film coated tablets

novartis israel ltd - hydrochlorothiazide; valsartan - film coated tablets - valsartan 80 mg; hydrochlorothiazide 12.5 mg - valsartan and diuretics - valsartan and diuretics - co-diovan is indicated for the treatment of hypertension for patients in whom combination therapy is appropriate.

CO-DIOVAN 16012.5 MG FILM-COATED TABLETS Israel - English - Ministry of Health

co-diovan 16012.5 mg film-coated tablets

novartis israel ltd - hydrochlorothiazide; valsartan - film coated tablets - valsartan 160 mg; hydrochlorothiazide 12.5 mg - valsartan and diuretics - valsartan and diuretics - co-diovan is indicated for the treatment of hypertension in patients whose blood pressure is not adequately controlled by monotherapy. this fixed combination should be used as second-line therapy.

CO-DIOVAN 16025 MG FILM-COATED TABLETS Israel - English - Ministry of Health

co-diovan 16025 mg film-coated tablets

novartis israel ltd - hydrochlorothiazide; valsartan - film coated tablets - valsartan 160 mg; hydrochlorothiazide 25 mg - valsartan and diuretics - valsartan and diuretics - co-diovan is indicated for the treatment of hypertension in patients whose blood pressure is not adequately controlled by monotherapy. this fixed combination should be used as second-line therapy.